Indications:
Clarithromycin is indicated for the treatment of infections caused by susceptible strains of microorganisms, including:
1. Lower Respiratory Tract Infections (bronchitis, pneumonia): Caused by Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Legionella pneumophila, Bordetella pertussis, Staphylococcus aureus, Mycoplasma pneumoniae, or Chlamydophila pneumonia, etc.;
2. Upper Respiratory Tract Infections (pharyngitis, sinusitis): Caused by Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, viridans group streptococci, Neisseria gonorrhoeae, Staphylococcus aureus, or anaerobic bacteria, etc.;

3. Skin and Soft Tissue Infections (folliculitis, cellulitis, erysipelas): Caused by Staphylococcus aureus, Streptococcus pyogenes, Cutibacterium acnes, or viridans group streptococci, etc.;
4. Localized or Disseminated Infections: Caused by Mycobacterium avium or Mycobacterium intracellulare (localized/disseminated), and localized infections caused by Mycobacterium chelonae, Mycobacterium fortuitum, or Mycobacterium kansasii;
5. Prophylaxis of Disseminated Mycobacterial Infections: For HIV-infected patients with CD4 lymphocyte counts ≤100/mm³ to prevent disseminated Mycobacterium avium complex (MAC) disease;
6. Helicobacter pylori Eradication: Clarithromycin is also indicated for H. pylori eradication in combination with gastric acid inhibitors, thereby reducing the recurrence of duodenal ulcers.
7. Odontogenic infections: Treatment of odontogenic infections caused by susceptible pathogens. The in vitro antimicrobial spectrum of Clarithromycin is detailed in the [Pharmacology and Toxicology].

Strength:0.25g、0.5g

National Drug Approval Number:H20046345、H20183467